Harrow to acquire global rights to TYRVAYA nasal spray from Viatris
The $30 million upfront deal, with up to $70 million more tied to sales milestones, adds a second dry eye mechanism alongside Harrow's VEVYE franchise.
SEC filing
Latest
9 stories
Tuesday, September 15
Thursday, September 10
Viatris registers Phase 4 abuse-potential trial of gabapentin plus oxycodone
Friday, August 21
Viatris: Ocuphire trial results posted, Amnesteem label update, gabapentin abuse study completed
Tuesday, August 11
Mylan wins FDA approval for labeling supplement on metformin ER tablets
Thursday, August 6
Viatris raises 2026 guidance, reports FDA approvals and Tyrvaya sale in Q2 update
Viatris lifted full-year guidance midpoints, won FDA approval for a new contraceptive patch, and agreed to sell Tyrvaya rights to Harrow as it navigates manufacturing disruptions in India.
SEC filing